Pfizer is positioning for a potential long-term rebound following a steep post-COVID revenue decline and a drop of over 50% ...

Despite the modest revenue outlook, Pfizer’s earnings per share (EPS) forecast for 2025 is encouraging. The company projects adjusted diluted EPS of $2.80 to $3.00, representing a 2% year-over-year ...

Despite the modest revenue outlook, Pfizer’s earnings per share (EPS) forecast for 2025 is encouraging. The company projects adjusted diluted EPS of $2.80 to $3.00, representing a 2% year-over ...

Pfizer is expected to announce its second-quarter results next month, and analysts predict a single-digit drop in the company’s bottom-line figure.

Q2 earnings growth for the S&P 500 index of +4.7% improves to +6.7% once the Energy sector’s drag is removed from the aggregate numbers, ... Bank Earnings Outlook Improving.

Pfizer (PFE) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one of the ...